Comparison
Both are approved GLP-1 receptor agonists, but tirzepatide's additional GIP receptor agonism differentiates its metabolic profile and reported weight-loss depth.
| Attribute | Tirzepatide | Semaglutide |
|---|---|---|
| Full name | Tirzepatide (Mounjaro / Zepbound) | Semaglutide (Ozempic / Wegovy / Rybelsus) |
| Class | Dual GLP-1 / GIP agonist | GLP-1 mono-agonist |
| Mechanism | Activates both GLP-1 and GIP receptors — GIP agonism potentiates insulin response and modulates adipocyte activity | Selective GLP-1 receptor agonism — increases insulin secretion, suppresses glucagon, slows gastric emptying, promotes satiety |
| Half-life | ~5 days | ~1 week |
| Commonly reported doses | Commonly reported doses range from 2.5 to 15 mg/week SubQ | Commonly reported doses range from 0.25 to 2.4 mg/week SubQ; 3–14 mg/day oral |
| Routes | SubQ | SubQ, oral |
| Primary reported use | T2D (Mounjaro), obesity (Zepbound) — FDA-approved | T2D (Ozempic), obesity (Wegovy), cardiovascular risk reduction — FDA-approved |
The GIP receptor is the defining pharmacological difference between the two compounds. Semaglutide is a pure GLP-1 agonist; tirzepatide was engineered to activate both GLP-1 and GIP receptors simultaneously. GIP agonism appears to potentiate insulin secretion beyond what GLP-1 alone achieves, and may modulate adipocyte metabolism in ways that contribute to the greater weight-loss depth observed in SURMOUNT trials compared with STEP trials. This dual-receptor activity represents a meaningful mechanistic divergence rather than a simple dose-scaling difference.
Phase 3 clinical trial data provides the clearest head-to-head context. SURMOUNT-1 (tirzepatide, obesity indication) demonstrated approximately 20% body weight reduction at the 15 mg maintenance level; STEP 1 (semaglutide 2.4 mg, obesity indication) demonstrated approximately 15%. The SURPASS-2 trial directly compared tirzepatide against semaglutide 1 mg in patients with type 2 diabetes and showed greater HbA1c reduction and greater body weight reduction with tirzepatide across all doses tested — providing the most direct comparative evidence currently available.
Cardiovascular outcome data represents an important asymmetry. Semaglutide has more mature cardiovascular evidence, including SUSTAIN-6 and the SELECT trial, which demonstrated cardiovascular risk reduction in a broad population. Tirzepatide's SURPASS-CVOT is ongoing, meaning the cardiovascular outcome evidence base for tirzepatide remains incomplete relative to semaglutide. This asymmetry in evidence depth may be material to researchers specifically prioritising cardiac endpoints.
Both compounds share GLP-1 receptor agonism as their foundational mechanism. GLP-1 receptor activation increases glucose-dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying, and promotes satiety signalling in the hypothalamus. This shared pathway explains the broadly similar clinical profile — including glucose lowering, appetite suppression, and GI side-effect pattern.
Tirzepatide additionally engages the glucose-dependent insulinotropic polypeptide (GIP) receptor. Prior to tirzepatide's clinical development, GIP receptor agonism was widely considered insufficient for meaningful weight loss based on earlier research. Tirzepatide's Phase 3 data reversed that expectation — the dual-agonist approach produced outcomes consistently exceeding pure GLP-1 agonism. Current mechanistic hypotheses centre on GIP's role in potentiating insulin response and potentially influencing adipocyte lipid handling, though the precise contribution of GIP agonism to the observed weight-loss magnitude remains an active area of investigation.
Research has investigated both compounds for their potential role in type 2 diabetes management and obesity. Both carry FDA approval in these indications. Beyond the shared use cases, research trajectories diverge somewhat.
Research has investigated semaglutide for its potential role in cardiovascular risk reduction (SELECT trial, approved indication extension), and early-stage data has examined potential neuroprotective and metabolic effects including exploratory Alzheimer's disease research.
Research has investigated tirzepatide for its potential role in non-alcoholic steatohepatitis (NASH), where early data has been notable, and heart failure with preserved ejection fraction (HFpEF), where SUMMIT trial data has been reported. These areas reflect the metabolic breadth of dual GLP-1/GIP agonism.
Tirzepatide
Commonly reported protocols initiate at 2.5 mg/week SubQ, with titration upward every four weeks. Commonly reported maintenance doses range from 5 mg to 15 mg/week. The 15 mg level corresponds to the highest dose studied in SURMOUNT and SURPASS trials.
Semaglutide
Commonly reported protocols initiate at 0.25 mg/week SubQ, titrating over several weeks. For obesity research (Wegovy), titration continues to 2.4 mg/week. For T2D research (Ozempic), commonly reported maintenance doses range from 0.5 to 1 mg/week. Oral semaglutide (Rybelsus) commonly reported doses range from 3 to 14 mg/day.
Both compounds are administered subcutaneously on a weekly basis. Common injection sites in research protocols include the abdomen, thigh, or upper arm, with site rotation commonly reported to minimise local reactions.
Semaglutide is additionally available in an oral formulation (Rybelsus). Oral semaglutide has significantly lower bioavailability compared to the subcutaneous route and requires fasting administration — at least 30 minutes before food or drink — to achieve adequate absorption. Tirzepatide has no approved oral formulation; oral delivery research is ongoing. The oral route is therefore exclusive to semaglutide among currently available approved options.
Reported side effects in research and anecdotal accounts include a very similar profile for both compounds, reflecting their shared GLP-1 mechanism. Gastrointestinal effects are the most commonly reported: nausea, vomiting, diarrhoea, and constipation. These are typically most pronounced during dose titration and tend to attenuate over time.
Injection site reactions (redness, discomfort, nodule formation) are reported with both compounds at subcutaneous administration sites. Fatigue and reduced appetite extending beyond the intended effect are also noted anecdotally.
Both compounds share class-level signals for rare but serious effects including pancreatitis, gallbladder disease, and gastroparesis. These signals are present across the GLP-1 agonist class and are not specific to either compound. Thyroid C-cell concerns identified in rodent studies carry a class-level label warning, though human clinical relevance at approved doses remains under evaluation.
Researchers and clinicians commonly select tirzepatide where greater weight-loss depth is a primary research variable, where dual GLP-1/GIP agonist mechanisms are specifically being studied, or where the NASH and HFpEF data are relevant to the research question.
Semaglutide is more commonly selected where cardiovascular outcome data is a relevant consideration (leveraging SELECT and SUSTAIN-6 evidence), where a longer post-marketing real-world safety record is weighted, or where the oral administration route is specifically required. Semaglutide's longer tenure on the market also means a larger body of real-world pharmacovigilance data exists.
Combining tirzepatide and semaglutide is not an appropriate research approach. Both compounds activate the GLP-1 receptor as a primary mechanism; stacking two GLP-1 agonists would duplicate that receptor engagement without providing complementary or additive benefit through distinct pathways. The practical effect would be amplification of GI side effects — nausea, vomiting, gastroparesis risk — without a mechanistic rationale for the combination. Researchers investigating these compounds select one approach based on the specific mechanism and outcome data relevant to their protocol.
Researchers commonly choose tirzepatide when weight reduction magnitude is the primary research variable — Phase 3 data consistently shows greater depth of weight loss versus semaglutide — or when dual-agonist GLP-1/GIP mechanisms are the specific focus of investigation. Tirzepatide is also the relevant choice when NASH or HFpEF data are pertinent to the research question.
Researchers commonly choose semaglutide when cardiovascular outcome data is relevant to the protocol (semaglutide carries demonstrated CV risk reduction evidence), when oral administration is required (semaglutide-only option), or when a longer real-world post-marketing safety record is an important consideration. For protocols where the GLP-1 mono-agonist mechanism specifically matters — rather than the dual-agonist profile — semaglutide provides a cleaner mechanistic baseline.
Does tirzepatide work better than semaglutide for weight loss?
Phase 3 trial data — including the head-to-head SURPASS-2 trial and indirect comparison of SURMOUNT-1 versus STEP 1 — consistently shows greater body weight reduction with tirzepatide. SURMOUNT-1 reported approximately 20% body weight reduction at 15 mg; STEP 1 reported approximately 15% with semaglutide 2.4 mg. However, individual response varies meaningfully, and both are research-grade approaches with demonstrated efficacy. Population-level trial outcomes do not predict individual outcomes.
Is semaglutide safer than tirzepatide?
Both compounds have undergone extensive Phase 3 clinical trials with large populations and have demonstrated acceptable safety profiles sufficient for regulatory approval. The meaningful distinction is that semaglutide has more years of real-world post-marketing pharmacovigilance data, providing a broader signal-detection base. Tirzepatide's longer-term real-world safety record is still accruing given its more recent approval timeline. Reported side effects in research and anecdotal accounts are broadly similar between the two.
What is the difference between Mounjaro and Ozempic?
Mounjaro (tirzepatide) and Ozempic (semaglutide) are different drugs with different mechanisms. Mounjaro activates both the GLP-1 and GIP receptors; Ozempic activates only the GLP-1 receptor. Head-to-head trial data (SURPASS-2) has reported greater HbA1c reduction and greater body weight reduction with tirzepatide (Mounjaro) compared to semaglutide (Ozempic) at commonly studied doses. For weight management specifically, Zepbound (tirzepatide) compares to Wegovy (semaglutide) — phase 3 data shows approximately 20% vs 15% body weight reduction respectively.
Can I switch from semaglutide to tirzepatide?
This is a medical decision that falls outside a research-information framing. Researchers examining transition protocols or washout considerations should consult current pharmacological guidance and clinical literature. The compounds share GLP-1 receptor activity and overlap in mechanism, which may have practical implications for timing of any transition.
Related Comparisons
Protocol Pages